Stem Cell Sciences goes US
Wednesday, 04 March, 2009
Technology company Stem Cell Sciences (SCS) is to be sold to Delaware’s StemCells Inc for close to US$5 million.
SCS, which has a research laboratory in Melbourne and is headquartered in Cambridge in the UK, has an impressive portfolio of IP based around technologies for stem cell research including cell-based assays, gene delivery vehicles, cell media and methodologies.
In a statement, the companies said it was expected that SCS’s 20 full-time staff will be retained if the deal goes ahead. Agreement has already been received from 30 per cent of SCS shareholders.
An EGM to vote on the deal will be held in London on 27 March.
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
AI-driven manufacturing: lessons from the life sciences industry
The use of artificial intelligence for batch monitoring and digital twin development is...
Does paracetamol use in pregnancy cause autism? Experts respond
White House Press Secretary Karoline Leavitt says there is "mounting evidence finding a...
